Abstract
Objectives: To review the evidence of the involvement of the Wnt signalling pathway in mood disorders and in the action of drugs used to treat these disorders.
Methods: We performed a careful PubMed search using as keywords all possible terms relevant to the Wnt pathway and crossing them with each of four areas, i.e., developmental effects, behavioural effects, mood disorders, and drugs used in their treatment. Papers were selected on the basis of their content and their data used for discussion. Results: Neurodevelopmental and behavioural data point to the possibility of involvement of the Wnt pathway in the pathophysiology of mood disorders. Clinical and post-mortem data are not sufficient to corroborate a definite role for Wnt alterations in any mood disorder. Combining genetic and pharmacological data, we may state that glycogen synthase kinase is the key molecule in bipolar disorder, as it is connected with many other signalling pathways that were shown to be involved in mood disorders, while Wnt molecules in the hippocampus appear to be mainly involved in depressive disorders. Conclusions: Altered Wnt signalling may play a role in the pathophysiology of mood disorders, although not a central one. It is premature to draw conclusions regarding the possible usefulness of Wnt manipulations in the treatment of mood disorders.Keywords: Wingless (Wnt) signalling, Mood Disorders, Bipolar Disorder, Major Depression, Antidepressant Drugs, Mood Stabilising Agents, Antipsychotic Drugs
Current Neuropharmacology
Title:The Wnt Pathway in Mood Disorders
Volume: 10 Issue: 3
Author(s): Giulia Serra, Paolo Girardi, Ferdinando Nicoletti, Antonio Del Casale, Chiara Rapinesi, Daniele Serata, Alexia E. Koukopoulos, Stefano Maria Tamorri, Valeria Savoja, Giovanni Manfredi, Silvia Romano, Gabriele Sani, Carla Ludovica Telesforo, Nicoletta Girardi, Matteo Caloro, Alessio Simonetti, Giulio Maria Porfiri, Isabella Panaccione, Giorgio D. Kotzalidis, Alberto Maria Forte and Flavia Napoletano
Affiliation:
Keywords: Wingless (Wnt) signalling, Mood Disorders, Bipolar Disorder, Major Depression, Antidepressant Drugs, Mood Stabilising Agents, Antipsychotic Drugs
Abstract: Objectives: To review the evidence of the involvement of the Wnt signalling pathway in mood disorders and in the action of drugs used to treat these disorders.
Methods: We performed a careful PubMed search using as keywords all possible terms relevant to the Wnt pathway and crossing them with each of four areas, i.e., developmental effects, behavioural effects, mood disorders, and drugs used in their treatment. Papers were selected on the basis of their content and their data used for discussion. Results: Neurodevelopmental and behavioural data point to the possibility of involvement of the Wnt pathway in the pathophysiology of mood disorders. Clinical and post-mortem data are not sufficient to corroborate a definite role for Wnt alterations in any mood disorder. Combining genetic and pharmacological data, we may state that glycogen synthase kinase is the key molecule in bipolar disorder, as it is connected with many other signalling pathways that were shown to be involved in mood disorders, while Wnt molecules in the hippocampus appear to be mainly involved in depressive disorders. Conclusions: Altered Wnt signalling may play a role in the pathophysiology of mood disorders, although not a central one. It is premature to draw conclusions regarding the possible usefulness of Wnt manipulations in the treatment of mood disorders.Export Options
About this article
Cite this article as:
Serra Giulia, Girardi Paolo, Nicoletti Ferdinando, Del Casale Antonio, Rapinesi Chiara, Serata Daniele, E. Koukopoulos Alexia, Maria Tamorri Stefano, Savoja Valeria, Manfredi Giovanni, Romano Silvia, Sani Gabriele, Ludovica Telesforo Carla, Girardi Nicoletta, Caloro Matteo, Simonetti Alessio, Maria Porfiri Giulio, Panaccione Isabella, D. Kotzalidis Giorgio, Maria Forte Alberto and Napoletano Flavia, The Wnt Pathway in Mood Disorders, Current Neuropharmacology 2012; 10 (3) . https://dx.doi.org/10.2174/157015912803217279
DOI https://dx.doi.org/10.2174/157015912803217279 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Differential Susceptibility of Naive and Differentiated PC-12 Cells to Methylglyoxal-Induced Apoptosis: Influence of Cellular Redox
Current Neurovascular Research Antiviral Immunotherapy for Mosquito-Borne Flaviviruses: A Review of Current Status
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Modulation of GSTP1-1 Oligomerization by Electrophilic Inflammatory Mediators and Reactive Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Acetylenic Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Advances in α(v)β(3) Integrin-Targeting Cancer Therapy and Imaging with Radiolabeled RGD Peptides
Current Radiopharmaceuticals Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Anti-Cancer Agents in Medicinal Chemistry B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Current Medicinal Chemistry Caspase-8 as a Regulator of Tumor Cell Motility
Current Molecular Medicine Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models
Current Hypertension Reviews Calpains as a Target for Therapy of Neurodegenerative Diseases: Putative Role of Lithium
Current Drug Metabolism Anticonvulsant and Antinociceptive Actions of Novel Adenosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Gene Expression Abnormalities in Thymoma
Current Pharmacogenomics MYC-Mediated Synthetic Lethality for Treating Tumors
Current Cancer Drug Targets Is alpha-Synuclein Pathology a Target for Treatment of Neurodegenerative Disorders?
Current Alzheimer Research Serotonin Receptors of Type 6 (5-HT6): What can we Expect from them?
Current Medicinal Chemistry Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Current Pharmaceutical Biotechnology Macrocyclic Proteasome Inhibitors
Current Medicinal Chemistry Vitamin E-Related Inhibition of Monocyte 5-Lipoxygenase and Cardiovascular Outcome in Maintenance Hemodialysis Patients
Recent Patents on Inflammation & Allergy Drug Discovery Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Current Alzheimer Research